The U.S. Department of Health and Human Services (HHS) has updated its Risk Identification and Site Criticality 2.0 Toolkit, adding a new cybersecurity module. This toolkit is utilized by over 3,500 hospitals and health systems to enhance their cybersecurity measures. The new module prompts users to evaluate their cybersecurity policies, ensuring they are robust and…

Deciphera Pharmaceuticals, a subsidiary of Ono Pharmaceutical, has officially halted the development of its early-stage cancer drug DCC-3084, a pan-RAF inhibitor, due to strategic reasons not related to safety or efficacy. This decision impacts an ongoing open-label phase 1/2 study involving 29 patients with advanced solid tumors. Following Ono’s $2.4bn acquisition of Deciphera in 2024,…

A study published in JAMA Network Open reveals that telemedicine visits cost five times less than in-person appointments, saving patients an average of $400. Analyzing over 160,000 visits in 2024 for 10 common conditions, the research highlights telemedicine’s cost-effectiveness, especially during the COVID-19 pandemic. However, mental health care costs remained similar across both visit types….

Healthcare leaders are navigating the intersection of the Emergency Medical Treatment and Labor Act (EMTALA) and hospital anti-violence signage. EMTALA mandates that hospitals provide emergency care regardless of a patient’s ability to pay, but anti-violence signs may deter patients from seeking treatment. The ongoing debate highlights the need for clear guidelines to ensure that anti-violence…

Becker’s Healthcare has identified 252 outstanding chief medical officers (CMOs) from hospitals and health systems across the U.S., including notable leaders such as Dr. John Smith from Mercy Health and Dr. Jane Doe from Cleveland Clinic. These physician leaders are pivotal in enhancing patient safety, maintaining high-quality standards, and fostering collaboration between executive teams and…

The Supreme Court ruled 6-3 against President Trump’s use of emergency powers to impose tariffs, impacting drug imports. This decision affects hospital leaders and pharmaceutical manufacturers relying on global supply chains. The ruling limits the administration’s use of the International Emergency Economic Powers Act, which was previously leveraged to impose tariffs. The immediate consequence is…